From Name:
From Email:
To Name:
To Email:

Optional Message:


Genetic variation revealed that raises a risk linked to bisphosphonates

from Medical News Today

Researchers at the Columbia University College of Dental Medicine have identified a genetic variation that raises the risk of developing serious necrotic jaw bone lesions in patients who take bisphosphonates, a common class of osteoclastic inhibitors. The discovery paves the way for a genetic screening test to determine who can safely take these drugs. The study appears in the online version of the journal The Oncologist. Oral bisphosphonates are currently taken by some 3 million women in the United States for the prevention or treatment of osteoporosis. In addition, intravenous bisphosphonates are given to thousands of cancer patients each year to control the spread of bone cancer and prevent excess calcium (hypercalcemia) from accumulating in the blood. more


Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063